CorestemChemOn Officially Confirmed for Inclusion in U.S. NSF Regenerative Medicine Innovation Engine

Participation in WFIRM Cluster within the $9 Billion NSF Innovation Ecosystem

CorestemChemOn announced on December 10 that its official inclusion date in the “Piedmont Triad Regenerative Medicine Engine,” supported by the National Science Foundation (NSF), has been confirmed as December 31 of this year.

CorestemChemOn previously announced in October that it would participate in the NSF innovation ecosystem. After completing administrative procedures with the Wake Forest Institute for Regenerative Medicine (WFIRM), the final inclusion date was set for the end of the year. As a result, CorestemChemOn will become the first Korean company to participate in an official regenerative medicine engine supported by the NSF.

This confirmation follows WFIRM’s review of clinical phase 3 data and long-term real-world data (RWD) for CorestemChemOn’s ALS treatment “Neuronata-R.” After recognizing the scientific validity and clinical consistency of the data, WFIRM proposed official collaboration.

The NSF is a federal research funding agency with an annual budget of approximately 9 billion dollars (about 13 trillion won). Since 2022, it has designated 10 “Regional Innovation Engines” across the United States to support research and industry development in strategic fields. Among these, the “Piedmont Triad Regenerative Medicine Engine” is a regenerative medicine-focused cluster led by WFIRM, which has already secured an initial fund of 160 million dollars (about 220 billion won).

Alongside the confirmed inclusion, CorestemChemOn’s U.S. subsidiary has also finalized its legal entity relocation from Virginia to North Carolina, effective December 31. The company explained, “By aligning the dates of the entity relocation and NSF engine inclusion at the end of the year, we aim to unify tax, regulatory, and administrative procedures, and to operate U.S. research and business activities under a single system starting in 2026 as a strategic decision.”

Through this, CorestemChemOn will gain access to the research infrastructure and networks of NSF, WFIRM, and ReMDO. The company plans to accelerate: ▲ commercialization projects for ALS treatments, ▲ expansion of stem cell-based regenerative medicine research, ▲ advancement of FDA approval strategies, and ▲ expansion of local business operations for non-clinical research and CRO services.

A WFIRM official stated, “CorestemChemOn’s research and development direction aligns with the core goals of the regenerative medicine innovation hub promoted by the NSF,” adding, “Utilizing NSF’s infrastructure will further refine its clinical and commercialization strategies.”

Yang Gil-An, CEO of CorestemChemOn, commented, “This inclusion officially recognizes CorestemChemOn’s scientific capabilities within the U.S. public research and development system. We will complete the establishment of our North American base and fully implement our FDA approval and global commercialization strategies.”